Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Endocr Pract. 2011 May-Jun;17(3):e59-62. doi: 10.4158/EP10390.CR.

Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma.

Author information

  • 1Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

Abstract

OBJECTIVE:

To describe successful long-term tumor control in metastatic adrenocortical carcinoma, a relatively rare tumor with limited treatment options outside of surgery.

METHODS:

We present the clinical, radiologic, and pathologic findings in a patient with failure of or intolerance to conventional treatments for metastatic adrenocortical carcinoma.

RESULTS:

A 48-year-old man with adrenocortical carcinoma had disease progression with systemic therapies including mitotane, 5-fluorouracil, streptozotocin, bevacizumab, and external beam radiation therapy. Treatment with all chemotherapeutic drugs was ceased, and he was prescribed mebendazole, 100 mg twice daily, as a single agent. His metastases initially regressed and subsequently remained stable. While receiving mebendazole as a sole treatment for 19 months, his disease remained stable. He did not experience any clinically significant adverse effects, and his quality of life was satisfactory. His disease subsequently progressed after 24 months of mebendazole monotherapy.

CONCLUSION:

Mebendazole may achieve long-term disease control of metastatic adrenocortical carcinoma. It is well tolerated and the associated adverse effects are minor.

PMID:
21454232
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for MetaPress.com
    Loading ...
    Write to the Help Desk